Positive preliminary results from ATL1102 DMD Phase II trial
Filed with ASX · · 4 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- ATL1102 for DMD European regulatory interactions
- Acromegaly Early Access Program Status Update
- Phase II DMD clinical trial on track for dosing completion
- Phase II clinical trial in DMD Fully Enrolled
- Phase II clinical trial in DMD Update
Later from Percheron Therapeutics
- Response to ASX Price Query
- Appendix 4C - quarterly
- Dosing completed in ATL1102 Phase II DMD trial
- AGM Presentation 2019
- Suspension from Official Quotation
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics